CQP(SZ:000950)2018-10-25 16:00Financial Performance - Operating revenue for the reporting period was ¥6.32 billion, representing an increase of 8.97% year-on-year[8]. - Net profit attributable to shareholders decreased by 81.03% to ¥138.52 million compared to the same period last year[8]. - The net profit attributable to shareholders after deducting non-recurring gains and losses surged by 1,192.61% to ¥137.87 million[8]. - Basic earnings per share fell by 80.95% to ¥0.08, while diluted earnings per share also decreased by 80.95% to ¥0.08[8]. - The weighted average return on net assets was 1.96%, down by 9.73% compared to the previous year[8]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥19.10 billion, an increase of 25.63% compared to the end of the previous year[8]. - The company's accounts receivable increased by 37.15% to RMB 10,110,195,707.91 due to acquisitions and extended payment terms with hospital clients[18]. - Inventory rose by 30.08% to RMB 2,878,517,802.06, driven by acquisitions and expanded business scale[18]. - Goodwill increased by 196.53% to RMB 472,886,765.23 as a result of acquisitions in Gansu and Sichuan[18]. - Short-term borrowings surged by 214.77% to RMB 2,611,933,238.52 to meet operational needs[18]. - Long-term borrowings increased by 1540.41% to RMB 633,200,000.00, reflecting higher bank loans for business operations[18]. Cash Flow - The net cash flow from operating activities for the year-to-date was -¥1.78 billion, an increase of 81.12%[8]. - Cash outflow from operating activities increased by 81.12% to RMB -1,782,062,199.83, primarily due to extended collection periods from district hospital clients[21]. - Cash inflow from financing activities rose by 416.41% to RMB 2,191,653,559.25, driven by increased bank borrowings to meet operational funding needs[22]. Shareholder Information - The top shareholder, Chongqing Chemical Pharmaceutical Holding Group, holds 38.47% of the shares, totaling 664,900,806 shares[12]. - The total number of ordinary shareholders at the end of the reporting period was 43,569[12]. Expenses - Sales expenses decreased by 2.89% to RMB 585,973,307.78 compared to the same period last year[20]. - Management expenses fell by 14.57% to RMB 368,571,834.17, attributed to the exclusion of data from the divested Jianfeng Chemical segment[20]. - Financial expenses dropped by 41.75% to RMB 152,954,716.14, also due to the exclusion of the Jianfeng Chemical segment[20]. Investments - The total initial investment cost in securities amounted to approximately ¥75.31 million, with a fair value of ¥77.42 million at the end of the reporting period, resulting in a loss of ¥27.16 million[27]. - The company reported a significant loss of ¥31.83 million from the investment in Dongling International, with a fair value of ¥36.69 million at the end of the period[25]. - The investment in Chongqing Department Store showed a fair value increase of ¥608,050.74, with a total fair value of ¥6.40 million[25]. - The investment in Longjiang Power had a fair value of ¥65.95 million, reflecting a gain of ¥5.92 million during the reporting period[25]. - The total fair value of other securities investments held at the end of the period was ¥16.38 million[27]. Other Information - The company received government subsidies amounting to ¥8.58 million, primarily for industry development projects[9]. - The company did not engage in any entrusted financial management during the reporting period[28]. - There were no derivative investments reported during the period[29]. - The company did not conduct any research, communication, or interview activities during the reporting period[30]. - There were no violations regarding external guarantees during the reporting period[31]. - The company reported no non-operating fund occupation by controlling shareholders or related parties during the reporting period[32].